Drug intelligence / Profile preview

PT162

Development stage: Preclinical
Lead developer: Palisades Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

PT162 is a preclinical-stage small molecule drug candidate developed by Palisades Therapeutics for the treatment of oncology indications. It is designed as a dual modulator of the glucocorticoid receptor (GR) and the androgen receptor (AR). This dual-targeting approach aims to disrupt signaling pathways that contribute to tumor progression and therapeutic resistance, particularly in cancers where GR and AR activity are functionally linked or compensatory. As of current pipeline information, PT162 is in the preclinical phase of development.

Targets

GR (Glucocorticoid receptor)TP53 (Cellular Tumor Antigen p53 R175H)AR (Adrenergic receptors)

Beyond the preview

Go deeper on PT162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT162.

Explore the full profile